The global oral solid dosage contract manufacturing market size was estimated to be USD 36.61 billion in 2023 and is expected to reach USD 69.71 billion by 2034 with a CAGR of 6.03% during the forecast period 2024-2034. The market will increase as a result of factors such as the growing geriatric population, growing burden of chronic diseases, rising demand for generic drugs, and technological advancements as well as strategic partnerships and collaborations.
Utilizing cutting-edge technology in OSD manufacturing processes, such as automation and continuous production, improves productivity, cuts down on manufacturing time, and lowers error rates. This raises the standard and uniformity of the product. For instance, in December 2023, Boehringer Ingelheim and Lonza Group partnered to produce a new injectable treatment for chronic lung illness.
By product type, the tablets segment accounted for the highest revenue-grossing segment in the global oral solid dosage contract manufacturing market in 2023 owing to the widespread prevalence of chronic diseases, increased demand for generic medications, and the convenience and patient compliance associated with tablet formulations. For instance, Catalent, Inc. increased its footprint in the booming biopharmaceutical contract manufacturing sector in January 2024 by acquiring Macro Pharma Services. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for specialized formulations such as powders, granules, and effervescent tablets, which cater to diverse patient preferences and therapeutic needs.
By mechanism, the immediate-release segment accounted for the highest revenue-grossing segment in the global oral solid dosage contract manufacturing market in 2023 owing to the widespread demand for fast-acting medications, quick onset of therapeutic effects, and the versatility of immediate-release formulations in treating a broad range of acute and chronic conditions. For instance, Recipharm AB invested in a continuous manufacturing platform in October 2023 to improve the productivity and flexibility of OSD production. Additionally, the controlled release segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on enhancing patient adherence, reducing dosing frequency, and minimizing side effects associated with pharmaceutical treatments.
By end-user, the large-size companies segment accounted for the highest revenue-grossing segment in the global oral solid dosage contract manufacturing market in 2023 owing to the financial capabilities, extensive manufacturing infrastructure, and established global presence that enables them to undertake large-scale production contracts. For instance, Thermo Fisher Scientific launched a new service offering in January 2024 that targets smaller biotech businesses and is intended for pre-formulation and early development of OSDs. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for specialized and niche services within the oral solid dosage contract manufacturing market.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established pharmaceutical industry, a robust regulatory framework, and the presence of major pharmaceutical companies and contract manufacturing organizations (CMOs). Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the expanding pharmaceutical market, increasing investments in healthcare infrastructure, and the presence of a cost-effective and skilled workforce. For instance, Aenova Group diversified its service offering in January 2024 by entering into a strategic alliance with a CDMO that specialized in sterile injectables.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Utilizing cutting-edge technology in OSD manufacturing processes, such as automation and continuous production, improves productivity, cuts down on manufacturing time, and lowers error rates. This raises the standard and uniformity of the product. For instance, in December 2023, Boehringer Ingelheim and Lonza Group partnered to produce a new injectable treatment for chronic lung illness.
By product type, the tablets segment accounted for the highest revenue-grossing segment in the global oral solid dosage contract manufacturing market in 2023 owing to the widespread prevalence of chronic diseases, increased demand for generic medications, and the convenience and patient compliance associated with tablet formulations. For instance, Catalent, Inc. increased its footprint in the booming biopharmaceutical contract manufacturing sector in January 2024 by acquiring Macro Pharma Services. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for specialized formulations such as powders, granules, and effervescent tablets, which cater to diverse patient preferences and therapeutic needs.
By mechanism, the immediate-release segment accounted for the highest revenue-grossing segment in the global oral solid dosage contract manufacturing market in 2023 owing to the widespread demand for fast-acting medications, quick onset of therapeutic effects, and the versatility of immediate-release formulations in treating a broad range of acute and chronic conditions. For instance, Recipharm AB invested in a continuous manufacturing platform in October 2023 to improve the productivity and flexibility of OSD production. Additionally, the controlled release segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on enhancing patient adherence, reducing dosing frequency, and minimizing side effects associated with pharmaceutical treatments.
By end-user, the large-size companies segment accounted for the highest revenue-grossing segment in the global oral solid dosage contract manufacturing market in 2023 owing to the financial capabilities, extensive manufacturing infrastructure, and established global presence that enables them to undertake large-scale production contracts. For instance, Thermo Fisher Scientific launched a new service offering in January 2024 that targets smaller biotech businesses and is intended for pre-formulation and early development of OSDs. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for specialized and niche services within the oral solid dosage contract manufacturing market.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established pharmaceutical industry, a robust regulatory framework, and the presence of major pharmaceutical companies and contract manufacturing organizations (CMOs). Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the expanding pharmaceutical market, increasing investments in healthcare infrastructure, and the presence of a cost-effective and skilled workforce. For instance, Aenova Group diversified its service offering in January 2024 by entering into a strategic alliance with a CDMO that specialized in sterile injectables.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product Type, Mechanism, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Oral Solid Dosage Contract Manufacturing Market Report 2023 - 2034
Oral Solid Dosage Contract Manufacturing Market Analysis & Forecast by Product Type 2023 - 2034 (Revenue USD Bn)
- Tablets
- Capsules
- Powders
- Granules
- Others
Oral Solid Dosage Contract Manufacturing Market Analysis & Forecast by Mechanism 2023 - 2034 (Revenue USD Bn)
- Immediate Release
- Delayed Release
- Controlled Release
Oral Solid Dosage Contract Manufacturing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Large Size Companies
- Medium & Small Size Companies
- Others
Oral Solid Dosage Contract Manufacturing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Oral Solid Dosage Contract Manufacturing Market: Product Type Estimates & Trend Analysis
8. Oral Solid Dosage Contract Manufacturing Market: Mechanism Estimates & Trend Analysis
9. Oral Solid Dosage Contract Manufacturing Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Oral Solid Dosage Contract Manufacturing Market
12. Europe Global Oral Solid Dosage Contract Manufacturing Market
13. Asia Pacific Global Oral Solid Dosage Contract Manufacturing Market
14. Latin America Global Oral Solid Dosage Contract Manufacturing Market
15. MEA Global Oral Solid Dosage Contract Manufacturing Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Lonza Group
- Catalent Inc.
- Recipharm AB
- Pfizer CentreOne
- Patheon (now part of Thermo Fisher Scientific)
- Aenova Group
- Cambrex Corporation
- Evonik Industries AG
- Dr. Reddy's Laboratories
- Almac Group
- DPT Laboratories
- Fareva
- Granules India Ltd.
- Hetero Group
- Strides Pharma Science Limited.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 36.61 Billion |
| Forecasted Market Value ( USD | $ 69.71 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
